Chargement en cours...
Brief report: EGFR L858M/L861Q cis mutations confer selective sensitivity to afatinib
INTRODUCTION: Tyrosine kinase inhibitors (TKIs) have been developed to treat patients with epidermal growth factor receptor (EGFR)-mutant lung cancers. However, the therapeutic efficacy of TKIs in patients with uncommon EGFR mutations remains unclear. METHODS: Next-generation sequencing was performe...
Enregistré dans:
| Publié dans: | J Thorac Oncol |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5558893/ https://ncbi.nlm.nih.gov/pubmed/28088511 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2017.01.006 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|